Log In
BCIQ
Print this Print this
 

AU-4948, CA-4948

  Manage Alerts
Collapse Summary General Information
Company Aurigene Discovery Technologies Ltd.
DescriptionOral IL-1 receptor-associated kinase 4 (IRAK4) inhibitor
Molecular Target Interleukin-1 receptor-associated kinase 4 (IRAK4)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationB cell lymphoma
Indication DetailsTreat diffuse large B cell lymphoma (DLBCL)
Regulatory Designation
PartnerCuris Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/21/2015

Undisclosed

0

Undisclosed

Get a free BioCentury trial today